Foresight LabsA jacket, two journeys

European Economic AreaREACH

Report Suggests Restrictions On Methylenedianilines Amid Carcinogenic And Environmental Concerns

ECHA’s latest Assessment of Regulatory Needs highlights 15 methylenedianilines as candidates for regulatory risk management. With concerns spanning carcinogenicity to environmental persistence, the chemicals could face future restrictions, subject to further hazard confirmation.

Published in June 2025. Dates, deadlines and stages may have changed since.

Dr Steven Brennan

3 min readAI-drafted, expert reviewed

Paint coatings

A recent report has flagged 15 methylenedianilines for potential regulatory risk management, including possible future restrictions. Used in polymer production, adhesives, and coatings, these industrial chemicals raise concerns over carcinogenicity, mutagenicity, and environmental persistence—prompting ECHA to recommend further scrutiny and precautionary measures.

While no formal restrictions have yet been proposed, the report signals that the substances could face tightened controls under REACH if hazards are confirmed.

Why Methylenedianilines Are Under The Microscope

Methylenedianilines are a group of structurally similar aromatic amines primarily used by industrial and professional users in polymer manufacturing. Several substances in this group, such as 4,4'-methylenedianiline (MDA) and MOCA, are already classified as carcinogenic and included in REACH’s Authorisation List.

ECHA’s grouping approach, based on structural similarity and hazard profiles, highlights widespread risks: five substances are already identified as Substances of Very High Concern (SVHCs), and others display potential for skin sensitisation, repeated dose toxicity (STOT RE), or environmental harm such as aquatic toxicity and possible PBT/vPvB behaviour.

What The Report Suggests For Industry

While no immediate legislative action has been taken, ECHA recommends that the group of substances—particularly those already flagged for genotoxic carcinogenicity—be considered for restriction if further hazard confirmation is obtained. The concern stems not only from workplace exposure but also from residual content in finished articles that may lead to uncontrolled release during service life.

Suggested next steps include compliance checks, data generation, and hazard classification. Where hazards are confirmed, REACH restrictions could be used to manage exposure from both imported articles and professional uses, which are often less controlled than industrial settings.

Implications For Manufacturers, Importers And Downstream Users

The implications extend well beyond chemical manufacturers. Stakeholders across construction, automotive, electronics, and consumer goods sectors should assess the presence of these substances in their value chains. ECHA’s findings emphasise the need for proactive inventory management and supplier engagement—even in the absence of formal legislative proposals.

Professionals are advised to monitor the development of these assessments closely, as formal regulatory steps such as harmonised classification or SVHC identification could soon follow.

Questions about this change

Are methylenedianilines currently banned or restricted in the EU?

Not all methylenedianilines are restricted, but several—such as MDA and MOCA—are already subject to authorisation. Others may be added if further assessments confirm their hazards.

What steps should companies take in light of the ARN?

Businesses should assess whether these substances are present in their operations or supply chains. Preparing now—via chemical inventory reviews and supply chain checks—will help ensure readiness for any future regulatory actions.

Dr Steven Brennan

CEO and co-founder of Foresight, and a co-opted member of ECHA's Committee for Socio-economic Analysis. He holds a PhD in chemical engineering.

More from Dr Steven Brennan

Join 3,500+ professionals staying ahead

Foresight Weekly brings the week's regulatory changes across chemicals, product safety, sustainability, ESG and EHS into one email.

Free. Unsubscribe at any time.

Read by professionals at

  • Boeing
  • AstraZeneca
  • Siemens
  • PepsiCo
  • SpaceX